Guardant Health: Valuation Under Scrutiny Amid Obamacare Subsidy Extension Proposal

Guardant Health's stock surged after the White House proposed a two-year extension of Obamacare subsidies, enhancing revenue for healthcare companies. The stock has rallied 242.5% year-to-date and 50.8% over the past month, driven by strong policy tailwinds and optimistic revenue prospects. The company's valuation is a key focus, with a narrative fair value of $99 and a DCF model suggesting upside. Despite growing optimism, investors remain cautious about Guardant Health's long-term profitability challenges and financial risks.